Pfizer: It's Darkest Before The Dawn, Upgrading To 'Strong Buy'

Michael M. SantiagoIntroduction On December 21, 2023, I wrote about Pfizer Inc. (NYSE:PFE) stock for the first time after a long hiatus since initiating coverage in November 2021. Last time, I wrote about PFE appearing oversold and undervalued due to likely underestimated EPS forecasts for FY 2025 and beyond. I urged not to panic, but to think about building a long position at the low price levels. Unfortunately, the PFE stock has since significantly underperformed the broader market:  Seeking Alpha, my ...